T-cell Diagnostic Tests: COVID-19 Pushed Us, and We Can See Where This Leads
In late February 2020, when it became clear that COVID-19 was spreading around the world, our senior management team at Adaptive Biotechnologies took a gamble. We had a hunch that our ability to evaluate T-cell immunity, combined with advanced bioinformatics, could help the scientific community better understand the novel coronavirus. The entire world, it seemed, was focused on B-cell derived... Read More
Extending an Immune Medicine Platform Against the Common Foe
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.